Related Experiment Video
Updated: Jun 7, 2026
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors
Published on: December 16, 2022
[Inhibitory effect of 5F11-DXR immunoconjugate on human lung cancer cells]
Background:
To evaluate the inhibition effect of immunoconjugate of doxorubicin(DXR) with a monoclonal antibody, 5F11 on human lung cancer cells and its reversal effect on resistant lung cancer cells to chemotherapeutic drug.
Methods:
DXR was attached to 5F11 using dilute glutaraldehyde crossing.The antitumor activity of immunoconjugate, 5F11-DXR, against the sensitive antigen-positive cell line, A2, drug-resistant antigen-positive cell lines, 801-D and 801-DDXR, and antigen-negative cell line, ascite cancer cell was evaluated by human tumor cell cloning assay and dye exclusion assay.
Results:
According to the results of various assays, comparing with single DXR, 5F11-DXR could significantly increase the cytotoxicity to A2, 801-D and 801-DDXR cell lines with a DXR concentration of 0.4 μg/ml(P<0.05), and this difference was even more distinct to A2 cell line with lower concentration of DXR (0.04 μg/ml). However, there was no remarkable difference between 5F11-DXR and single DXR in cytotoxicity to antigen-negative ascite cancer cell(P>0.05).
Conclusions:
5F11-DXR can remarkably increase the cytotoxicity of DXR to the sensitive target cells and even effectively reverse the drug-resistant cell lines to DXR. There is no significant difference between 5F11-DXR and DXR in killing antigen-negative cancer cells.
Insights
This study shows that the immunoconjugate 5F11-doxorubicin (DXR) enhances DXR
Area of Science:
- Oncology
- Immunotherapy
- Drug Delivery
Context:
- Lung cancer exhibits resistance to conventional chemotherapy.
- Targeted drug delivery systems are being developed to overcome resistance.
- Monoclonal antibodies can be conjugated with chemotherapeutic agents for targeted delivery.
Purpose:
- To evaluate the efficacy of an immunoconjugate of doxorubicin (DXR) with the monoclonal antibody 5F11.
- To assess its inhibitory effect on human lung cancer cells.
- To determine its potential to reverse drug resistance in lung cancer cells.
Summary:
- The immunoconjugate 5F11-DXR was synthesized and tested against sensitive and drug-resistant human lung cancer cell lines.
- 5F11-DXR demonstrated significantly increased cytotoxicity compared to DXR alone in antigen-positive cell lines, including resistant ones.
- No significant difference in cytotoxicity was observed against antigen-negative cancer cells.
Impact:
- 5F11-DXR enhances doxorubicin's cytotoxicity against sensitive lung cancer cells.
- The immunoconjugate effectively reverses resistance in DXR-resistant lung cancer cell lines.
- This targeted approach offers a promising strategy for overcoming chemotherapy resistance in lung cancer.
